# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-338023
Filing Date
2026-08-06
Accepted
2026-08-06 16:12:29
Documents
56
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | trvi-20260630.htm iXBRL | 10-Q | 2071225
2 | EX-31.1 | trvi-ex31_1.htm | EX-31.1 | 18102
3 | EX-31.2 | trvi-ex31_2.htm | EX-31.2 | 18091
4 | EX-32.1 | trvi-ex32_1.htm | EX-32.1 | 12331
5 | EX-32.2 | trvi-ex32_2.htm | EX-32.2 | 12306
| Complete submission text file | 0001193125-26-338023.txt |  | 8512727

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | trvi-20260630.xsd | EX-101.SCH | 1023113
60 | EXTRACTED XBRL INSTANCE DOCUMENT | trvi-20260630_htm.xml | XML | 1639432

Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 261249173
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)